Keyphrases
Metastatic Breast Cancer
100%
Randomized Phase II Trial
100%
Fulvestrant
100%
Hormone-sensitive
100%
Cediranib
100%
Adverse Events
25%
Placebo
16%
Progression-free Survival
16%
Pharmacokinetics
16%
Objective Response Rate
16%
Clinical Benefit Rate
16%
Estrogen Receptor Antagonist
16%
Hazard Ratio
8%
Hypertension
8%
Baseline Characteristics
8%
Clinically Significant
8%
Serious Adverse Events
8%
Chemotherapy
8%
Postmenopausal Women
8%
Tolerability
8%
Estrogen
8%
Vascular Endothelial Growth Factor
8%
Estrogen Receptor
8%
Diarrhea
8%
Duration of Response
8%
Dose Reduction
8%
Hormone Receptor-positive Breast Cancer
8%
Vascular Endothelial Growth Factor Receptor (VEGFR)
8%
Clinical Activity
8%
Well-balancing
8%
Vascular Endothelial Growth Factor Signaling
8%
Signal Transduction Inhibitors
8%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Breast Cancer
100%
Fulvestrant
100%
Cediranib
100%
Adverse Event
33%
Placebo
16%
Progression Free Survival
16%
Vasculotropin
16%
Estrogen Receptor Antagonist
16%
Pharmacokinetics
16%
Chemotherapy
8%
Breast Cancer
8%
Tolerability
8%
Estrogen Receptor
8%
Hormone Receptor
8%
Diarrhea
8%
Vasculotropin Receptor
8%